Understanding
Biologic Allograft
Therapy
Lumera Medical offers Hyagen Medical biologic allograft products as part of a physician-led regenerative medicine program. This page is designed to help you understand what these products are, how they are regulated, and whether a consultation with Dr. Roberta Huang, MD may be appropriate for your situation.
A Field Built on
the Body’s Own Biology
Regenerative medicine is a broad field of clinical practice and research focused on supporting, augmenting, or working alongside the body’s own biological processes. It encompasses a range of approaches, including the use of biologic allografts — products derived from human tissue that are administered to support tissue function in a comparable area of the body.
Unlike pharmaceutical drugs, which are chemically synthesized and require FDA drug approval, certain biologic tissue products are regulated under a separate framework — FDA 21 CFR Part 1271 — when they are minimally manipulated and used for homologous purposes. This means the product performs a role consistent with its natural function in the donor tissue.
It is important to understand that regenerative biologic allografts are not approved drug therapies and are not intended to diagnose, treat, cure, or prevent any disease. Like all medical procedures, outcomes vary by individual. Candidacy and appropriateness are always determined by Dr. Huang through an individualized consultation.
The Science Behind
Allograft Therapy
Hyagen Medical products are derived from perinatal birth tissue — specifically the umbilical cord. They contain biologically active components including growth factors, cytokines, and extracellular vesicles that are naturally present in this tissue. When administered, these components are intended to act in a manner consistent with the tissue’s natural function in the body.
Hyagen Medical products originate from ethically donated perinatal umbilical cord blood. Donors are screened per American Association of Tissue Banks (AATB) standards. All products are manufactured under FDA HCT/P 361 guidelines and cryogenically preserved to maintain biological integrity.
“Minimally manipulated” is a specific FDA classification that means the product has not been processed in a way that alters its original biological characteristics. This distinguishes these allografts from experimental or investigational therapies and is a prerequisite for FDA HCT/P 361 classification.
“Homologous use” means the allograft is used to perform the same basic function in the recipient that it performed in the donor. Hyagen Medical; products are intended for homologous use only — a requirement of their FDA regulatory classification and a condition of how Dr. Huang administers them.
Three HCT/P Allograft
Products, One Standard of Quality
Lumera Medical offers three Hyagen Medical; biologic allograft products. Each is manufactured under FDA HCT/P 361 and AATB guidelines, cryogenically preserved, and intended for homologous use only. Dr. Huang determines which product, if any, is appropriate based on your individual consultation.
Hyagen Medical CV is a cellular allograft derived from donated perinatal placental umbilical cord blood. It contains cells naturally present in this tissue and is cryogenically preserved to maintain biological activity. As a minimally manipulated HCT/P, it is regulated under FDA Section 361 guidelines.
Hyagen Medical EV is a cell-free allograft derived from perinatal umbilical cord blood. It contains extracellular vesicles and biological signaling proteins — naturally occurring components involved in intercellular communication. Like all Hyagen Medical products, it is minimally manipulated and intended for homologous use only.
Hyagen Medical JL is a flowable suspension derived from Wharton’s Jelly, the connective tissue of the human umbilical cord. It is cryogenically preserved to retain naturally occurring growth factors, cytokines, and other biologically active components present in this tissue.
Candidacy Is Determined Individually
There is no universal answer to whether biologic allograft therapy is appropriate for any given person. Candidacy depends on a detailed review of your health history, current conditions, medications, and goals.
Dr. Huang evaluates each patient individually. She will discuss what these products are, what the administration process involves, and whether they may be relevant to your specific situation. She will also discuss alternatives and will not recommend a procedure that is not clinically appropriate for you.
The following outlines some of the general areas patients have asked about in relation to biologic allograft therapy. These are informational only and do not constitute medical advice or a recommendation for treatment.
Some patients with joint discomfort, soft tissue concerns, or musculoskeletal conditions have sought consultation about whether biologic allografts may be part of a broader care approach. Appropriateness is determined case by case.
Patients interested in supporting overall wellness and healthy aging have asked about regenerative biologics as part of a broader preventive or longevity-focused health program under physician guidance.
Some patients have inquired about biologic allograft applications in the context of skin health and aesthetic concerns. Any aesthetic application would be discussed in the context of your full health picture and Lumera’s broader service offering.
Questions about whether biologic allografts may play a supportive role during recovery from injury or procedure are best addressed directly with Dr. Huang, who will assess your specific circumstances.
The Consultation
& Care Process
Every patient journey begins with an individualized consultation with Dr. Roberta Huang, MD. No procedure is recommended or scheduled without that foundational conversation.
Contact Lumera by phone or through our online form. Our team will collect a brief health history ahead of your visit with Dr. Huang.
You will meet one-on-one with Dr. Roberta Huang, MD for 30–45 minutes. She will review your health history, discuss your concerns, and assess whether biologic allograft therapy is appropriate for your situation.
If Dr. Huang determines you may be a candidate, she will walk you through the relevant product, the administration process, realistic expectations, and alternatives. Questions are encouraged.
You will receive and review a detailed informed consent document that explains the product classification, intended use, and what the procedure involves. No procedure moves forward without your complete understanding and written consent.
Your procedure is performed by Dr. Huang in our clinical setting using Hyagen Medical product protocols. The visit is typically completed within one hour.
Dr. Huang’s team contacts you at Day 7 and Day 30 to check in, document your experience, and answer any questions. Dr. Huang remains accessible throughout your care.
Dr. Roberta Huang
Dr. Roberta Huang, MD leads Lumera Medical’s regenerative medicine program. Every patient consultation, product selection decision, and procedure is conducted or directly overseen by Dr. Huang — not delegated to non-physician staff.
Dr. Huang has completed Hyagen Medical’s FDA-aligned provider training, which covers regulatory requirements, appropriate clinical language, patient education, and compliant product administration. She approaches regenerative biologics with the same evidence-informed, patient-first framework that guides all care at Lumera.
During your consultation, Dr. Huang will be direct with you about what is known, what is not yet fully understood, and whether she believes biologic allograft therapy is appropriate for you personally. She will not recommend a procedure that she does not believe is clinically justified.
Frequently Asked Questions
These are the questions patients ask most often. They are answered factually and without promotional framing.
HCT/P stands for Human Cells, Tissues, and Cellular and Tissue-Based Products. An allograft is a tissue product derived from a donor (in this case, ethically donated perinatal birth tissue) and administered to a recipient.
Under FDA regulations (21 CFR Part 1271), certain HCT/Ps that are minimally manipulated and used for homologous purposes are regulated under Section 361 of the Public Health Service Act. This means they do not require the same premarket approval process as pharmaceutical drugs, but are still subject to FDA registration, screening, and manufacturing requirements.
Hyagen Medical products are not FDA-approved drug therapies. They are regulated as HCT/P allografts under FDA 21 CFR Part 1271, Section 361 — a separate regulatory classification that applies to minimally manipulated tissue products used for homologous purposes.
This is an important distinction. These products do not go through the same clinical trial and approval process as drugs. They are subject to FDA registration, AATB-accredited manufacturing standards, donor screening requirements, and current Good Tissue Practice (cGTP) regulations.
All Hyagen Medical products are derived from ethically donated perinatal birth tissue — specifically the umbilical cord. Donors give informed consent and are screened for communicable diseases per AATB standards. No embryonic tissue is used. Tissue is donated, not purchased.
We do not make claims that Hyagen Medical products treat, cure, or prevent any specific medical condition. These are biologic allografts intended for homologous use — meaning they perform the same basic function or functions in the recipient as they do in the donor.
Whether they are appropriate for your specific situation is a clinical determination made by Dr. Huang during your consultation, based on your individual health history, goals, and circumstances. Patients have sought consultation for a range of musculoskeletal, wellness, and aesthetic concerns — but no two situations are the same.
Like all medical procedures, biologic allograft administration carries a success and failure rate and individual outcomes will vary. Potential risks include injection-site reactions, infection, and the possibility that the procedure may not achieve the desired outcome.
Dr. Huang will discuss the specific risk profile with you during your consultation. She follows documented adverse event protocols and will conduct follow-up contact at Day 7 and Day 30 after any procedure.
Biologic allograft therapy is not covered by insurance and is an elective, out-of-pocket service. A clear financial agreement will be reviewed and signed by you prior to any procedure. We will not proceed without your complete understanding of all costs involved.
The FDA has raised concerns about clinics marketing unapproved regenerative medicine products with unsupported claims. Questions worth asking any clinic include: Is the product classified as an HCT/P under Section 361 or Section 351? Is it manufactured by an AATB-accredited tissue bank? Has the administering physician completed provider training from the distributor? Are you being given a clear, written informed consent document?
At Lumera, Dr. Huang administers only Hyagen Medical products, which are manufactured to FDA HCT/P 361 and AATB standards. She has completed Hyagen Medical’s FDA-aligned provider training. All patients receive a written informed consent document before any procedure is performed.
Start with a Conversation
The Right Next Step Is
an Honest Consultation
If you have questions about biologic allograft therapy, Dr. Roberta Huang, MD is the right person to answer them. The consultation is educational and individualized — it begins with listening to you, not with a recommendation already made.
Questions before booking? [1-503-852-9680]
Important Regulatory Disclosure: Hyagen Medical CV, Hyagen Medical EV, and Hyagen Medical JL are Human Cellular and Tissue-Based Products (HCT/Ps) regulated under FDA 21 CFR Part 1271, Section 361, and manufactured in compliance with American Association of Tissue Banks (AATB) guidelines. All products are minimally manipulated and intended for homologous use only. These products are not FDA-approved drug therapies and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Individual results will vary. Like all medical procedures, there is a success and failure rate. Clinical candidacy is determined through an individualized physician consultation with Dr. Roberta Huang, MD. Lumera Medical does not guarantee any specific clinical outcome. Regenerative biologic allograft services are elective and not covered by insurance.
